Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 with efficacy progressively increasing throughout the treatment ...

Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...

Analyzing patient health care notes recorded during millions of medical appointments at GPs and hospitals across England has ...

Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15.

Children who have multiple food allergies (FAs) and allergies to milk and eggs are more likely to have early-onset atopic dermatitis (AD).

The two-time U.S. Olympic gold medalist gymnast opens up about her skin condition, her fashion dos and don’ts for eczema, and ...

Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...

Corvus Pharma (CRVS) stock surges as the company plans a Phase 2 trial for its lead asset against eczema following ...

Winters are known to worsen symptoms of eczema due to dropping temperatures.It is believed that around 8 million people in ...

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

Millions of Brits with eczema are almost twice as likely to suffer agonising eye and bowel conditions, research suggests.